Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ANIK logo ANIK
Upturn stock ratingUpturn stock rating
ANIK logo

Anika Therapeutics Inc (ANIK)

Upturn stock ratingUpturn stock rating
$10.58
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ANIK (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $21.33

1 Year Target Price $21.33

Analysts Price Target For last 52 week
$21.33Target price
Low$10.47
Current$10.58
high$29.11

Analysis of Past Performance

Type Stock
Historic Profit -3.21%
Avg. Invested days 59
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 153.67M USD
Price to earnings Ratio -
1Y Target Price 21.33
Price to earnings Ratio -
1Y Target Price 21.33
Volume (30-day avg) 3
Beta 0.65
52 Weeks Range 10.47 - 29.11
Updated Date 06/30/2025
52 Weeks Range 10.47 - 29.11
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.74

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -48.48%
Operating Margin (TTM) -16.37%

Management Effectiveness

Return on Assets (TTM) -1.73%
Return on Equity (TTM) -6.07%

Valuation

Trailing PE -
Forward PE 19.12
Enterprise Value 125877761
Price to Sales(TTM) 1.31
Enterprise Value 125877761
Price to Sales(TTM) 1.31
Enterprise Value to Revenue 1.08
Enterprise Value to EBITDA 163.48
Shares Outstanding 14341400
Shares Floating 10280506
Shares Outstanding 14341400
Shares Floating 10280506
Percent Insiders 4.91
Percent Institutions 90.28

Analyst Ratings

Rating 2
Target Price 21.33
Buy 1
Strong Buy 2
Buy 1
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Anika Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Anika Therapeutics Inc. was founded in 1992. It focuses on developing, manufacturing, and commercializing therapeutic products based on hyaluronic acid (HA) technology for tissue protection, healing, and repair.

business area logo Core Business Areas

  • Joint Health: Viscosupplementation products like MONOVISC and ORTHOVISC for osteoarthritis pain relief.
  • Early Intervention: Products focused on pain management and tissue regeneration in early stages of osteoarthritis and related conditions.
  • Sports Medicine: Products for soft tissue repair and regenerative solutions for sports-related injuries.
  • Regenerative Solutions: Products related to cell therapy and healing of damaged tissue.

leadership logo Leadership and Structure

The leadership team includes Cheryl R. Blanchard, Ph.D. (President and CEO). The company has a typical corporate structure with departments such as R&D, sales, marketing, and operations.

Top Products and Market Share

overview logo Key Offerings

  • MONOVISC: A single-injection viscosupplement for osteoarthritis knee pain. Competitors include products from Sanofi (SYNVISC), Zimmer Biomet (Gel-One), and Seikagaku (ARTZ). Market share data unavailable without subscription services. Sales data not publicly available on a per-product basis, only total revenue is announced.
  • ORTHOVISC: A multi-injection viscosupplement for osteoarthritis knee pain. Competitors include products from Sanofi (SYNVISC), Zimmer Biomet (Gel-One), and Seikagaku (ARTZ). Market share data unavailable without subscription services. Sales data not publicly available on a per-product basis, only total revenue is announced.
  • HYALOFAST: Hyaluronic acid-based scaffold for cartilage regeneration. Competitors include Smith+Nephew. Market share data unavailable without subscription services. Sales data not publicly available on a per-product basis, only total revenue is announced.

Market Dynamics

industry overview logo Industry Overview

The orthopedic and regenerative medicine market is growing due to aging populations, increasing sports injuries, and demand for minimally invasive procedures.

Positioning

Anika is positioned as a specialty orthopedic company focusing on HA-based therapies with a portfolio of branded products. Competitive advantage lies in its HA technology and established presence in viscosupplementation.

Total Addressable Market (TAM)

The TAM for osteoarthritis treatment and regenerative medicine is estimated in the billions of dollars annually. Anika is positioned to capture a portion of this market through its existing product portfolio and pipeline.

Upturn SWOT Analysis

Strengths

  • Proprietary HA Technology
  • Established Brand Recognition (MONOVISC, ORTHOVISC)
  • Focus on Specialty Orthopedics
  • Distribution Network

Weaknesses

  • Reliance on Viscosupplementation Market
  • Limited Product Diversification
  • Competition from Larger Players
  • Dependence on Reimbursement Policies

Opportunities

  • Expansion into New Geographies
  • Development of Novel HA-based Therapies
  • Acquisitions of Complementary Technologies
  • Partnerships with Larger Orthopedic Companies

Threats

  • Pricing Pressure from Competitors
  • Changes in Reimbursement Policies
  • Emergence of New Treatment Modalities
  • Product Liability Litigation

Competitors and Market Share

competitor logo Key Competitors

  • SNY (Sanofi)
  • ZBH (Zimmer Biomet)
  • JNJ (Johnson & Johnson)

Competitive Landscape

Anika competes with larger orthopedic companies and specialized viscosupplementation providers. Its competitive advantage lies in its HA technology and focus, but it faces challenges from larger companies with greater resources.

Major Acquisitions

Parcus Medical, LLC

  • Year: 2019
  • Acquisition Price (USD millions): 26
  • Strategic Rationale: Expanded Anika's sports medicine portfolio with soft tissue fixation and sports medicine products.

Growth Trajectory and Initiatives

Historical Growth: Historical growth trajectory not available without real-time data feed.

Future Projections: Future projections unavailable without access to proprietary analyst reports.

Recent Initiatives: Recent initiatives not available without access to real-time data feed.

Summary

Anika Therapeutics is a specialty orthopedic company with established products in viscosupplementation. Its strength lies in its HA technology, however, it faces competition from larger, more diversified players. Future growth depends on expanding its product portfolio and geographical reach, and mitigating threats from changing reimbursement policies and emerging technologies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Market Reports (General)
  • Analyst Reports (General)

Disclaimers:

This analysis is based on publicly available information and general market knowledge. Actual financial data and market share figures may vary. This is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Anika Therapeutics Inc

Exchange NASDAQ
Headquaters Bedford, MA, United States
IPO Launch date 1993-04-29
President, CEO & Director Dr. Cheryl Renee Blanchard Ph.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 288
Full time employees 288

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.